These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2446068)

  • 1. The rationale for ketanserin therapy in hypertension.
    Hansson L; Hedner T
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S39-44. PubMed ID: 2446068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
    Amstein R; Fetkovska N; Pletscher A; Bühler FR
    J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension.
    Hedner T; Persson B
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):317S-323S. PubMed ID: 3046635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of ketanserin on arterial pressure at rest and during physical exercise in essential arterial hypertension].
    Gambini G; Gradoli C; Proietti MG; Pinchi G; Fioroni E; Valori C
    Clin Ter; 1989 Jul; 130(2):101-7. PubMed ID: 2529082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Blockade of 5-HT2 receptors as a mechanism of antihypertensive action of ketanserin].
    Prostran M
    Srp Arh Celok Lek; 1994; 122(3-4):99-102. PubMed ID: 17972821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with ketanserin and ritanserin in hypertensive patients.
    Hedner T; Persson B
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S44-8. PubMed ID: 2459514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketanserin, hypertension, and chronic alcoholism: double-blind study in forty patients.
    de Lorenzo A; Ceccanti M; Assogna G; Romeo M; Cavaleri G; Attilia ML
    Int J Clin Pharmacol Res; 1988; 8(5):321-5. PubMed ID: 3068159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of ketanserin on blood pressure and platelets during cardiopulmonary bypass.
    Lichtenthal PR; Wade LD; Rossi EC
    Anesth Analg; 1987 Nov; 66(11):1151-4. PubMed ID: 3662060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
    Persson B; Gradin K; Pettersson A; Hedner T
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S22-4. PubMed ID: 2459509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related effects of 5-HT2 antagonists.
    Doyle AE
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S29-34. PubMed ID: 1717770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ketanserin in the treatment of the essential arterial hypertension associated with ischemic heart disease.
    Podoleanu D; Cotoi S
    Rom J Intern Med; 1996; 34(1-2):49-54. PubMed ID: 8908630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal hemodynamic effects of ketanserin therapy in essential hypertension.
    Ram CV; Gonzalez DG; Kaplan NM; Ralakis JM; Henderson JD; Lugo CE; Zachariah N
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S78-80. PubMed ID: 2446078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age and 5HT 2-receptor blockade with ketanserin in essential hypertension.
    Bühler FR; Amstein R
    Rev Port Cardiol; 1989 Sep; 8(9):621-4. PubMed ID: 2698721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J; Stott DJ; Robertson JI; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy].
    Beretta-Piccoli C; Amstein R; Bühler FR; Bertel O; Brunner HR; Follath F; Reutter F; Vallotton MB
    Schweiz Med Wochenschr; 1989 Mar; 119(12):399-406. PubMed ID: 2711155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive therapy with ketanserin: metabolic and hemodynamic effects.
    Levinson PD; Zimlichman R; Goldstein DS; Keiser HR
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):384-9. PubMed ID: 2465437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intravenous ketanserin on arterial and intracranial pressures in patients with systemic hypertension following intracerebral haemorrhage.
    Kay R; Poon WS; Nicholls MG
    J Hum Hypertens; 1993 Aug; 7(4):369-71. PubMed ID: 8410928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why are the antihypertensive effects of ketanserin age-related?
    Doyle AE
    J Cardiovasc Pharmacol; 1988; 12 Suppl 8():S124-31. PubMed ID: 2469894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and hemodynamic effects of antihypertensive treatment with ketanserin.
    Levinson PD; Zimlichman R; Goldstein DS; Brewer HB; Keiser HR
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):245S-248S. PubMed ID: 3415801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.